Protection of pancreatic β-cells against glucotoxicity by short-term
treatment with GLP-1
- Affiliated Author(s)
- 박재형; 송대규; 배기철; 임정근
- Alternative Author(s)
- Park, Jae Hyung; Song, Dae Kyu; Bae, Ki Cheor; Lim, Jeong Geun
- Journal Title
- Biochemical and Biophysical Research Communications
- ISSN
- 0006-291X
- Issued Date
- 2015
- Abstract
- Glucagon-like peptide-1 (GLP-1) reduces pancreatic β-cell apoptosis in type 2 diabetes. Glucotoxiciy is a main cause of β-cell apoptosis in type 2 diabetes. The aims of this study were to investigate the anti-apoptotic mechanisms of GLP-1 against glucotoxicity and whether physiological short-term treatment with GLP-1 can protect β-cells from glucotoxicity-induced apoptosis. GLP-1 treatment for only 30 min alleviated high glucose-induced β-cell apoptosis. The effect of GLP-1 was related with phosphoinositide 3-kinase (PI3K)/AKT-S473 phosphorylation. The increase in pAKT-S473 led to suppression of FoxO-1. GLP-1-induced AKT-S473 activation and FoxO-1 suppression were abolished by the selective inactivation of mTOR complex (mTORC) 2 using small interfering RNA directed towards the rapamycin-insensitive companion of mTOR. The protective effect of GLP-1 on β-cell apoptosis was also abolished by the selective inactivation of mTORC2. Hence, the protective effect of GLP-1 against glucotoxicity may be mediated by FoxO-1 suppression through the PI3K/mTORC2/AKT-S473 phosphorylation. This report provides evidence that short-term treatment with GLP-1 is beneficial to protect against glucotoxicity-induced β-cell apoptosis.
Keywords
Glucagon-like peptide-1;
Glucotoxiciy;
FoxO-1;
mTOR complex 2;
Pancreatic β-cell;
Type 2 diabetes
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.